-
Circ_005077 accelerates myocardial lipotoxicity induced by high-fat diet via CyPA/p47PHOX mediated ferroptosis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-15 Xinzhu Ni, Lian Duan, Yandong Bao, Jinyang Li, Xiaowen Zhang, Dalin Jia, Nan Wu
The long-term high-fat diet (HFD) can cause myocardial lipotoxicity, which is characterized pathologically by myocardial hypertrophy, fibrosis, and remodeling and clinically by cardiac dysfunction and heart failure in patients with obesity and diabetes. Circular RNAs (circRNAs), a novel class of noncoding RNA characterized by a ring formation through covalent bonds, play a critical role in various
-
Relationships of serum FGF23 and α-klotho with atherosclerosis in patients with type 2 diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-15 Jiao Bi, Mei Zheng, Ke Li, Siwei Sun, Zihang Zhang, Nana Yan, Xueping Li
Compelling evidence suggests that calcium/phosphorus homeostasis-related parameters may be linked to diabetes mellitus and cardiovascular events. However, few studies have investigated the association of fibroblast growth factor 23 (FGF23), α-klotho and FGF23/α-klotho ratio with atherosclerosis in patients with type 2 diabetes mellitus (T2DM). This study was designed to evaluate whether FGF23, α-klotho
-
Risk factors for and risk of all-cause and atherosclerotic cardiovascular disease mortality in people with type 2 diabetes and peripheral artery disease: an observational, register-based cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-15 Tarik Avdic, Hanne K. Carlsen, Aidin Rawshani, Soffia Gudbjörnsdottir, Zacharias Mandalenakis, Björn Eliasson
Type 2 diabetes (T2D) and peripheral artery disease (PAD) are recognized as independent risk factors contributing to excess mortality. Contemporary observational studies exploring the associations of risk factors, and risk of all-cause and atherosclerotic cardiovascular disease mortality in persons with T2D following the onset of incident peripheral artery disease are limited. The objectives of this
-
Clinically relevant plasma proteome for adiposity depots: evidence from systematic mendelian randomization and colocalization analyses Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-13 Min Cao, Bin Cui
The accumulation of visceral and ectopic fat comprise a major cause of cardiometabolic diseases. However, novel drug targets for reducing unnecessary visceral and ectopic fat are still limited. Our study aims to provide a comprehensive investigation of the causal effects of the plasma proteome on visceral and ectopic fat using Mendelian randomization (MR) approach. We performed two-sample MR analyses
-
Frail hypertensive older adults with prediabetes and chronic kidney disease: insights on organ damage and cognitive performance - preliminary results from the CARYATID study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-10 Gaetano Santulli, Valeria Visco, Michele Ciccarelli, Mario Nicola Vittorio Ferrante, Piero De Masi, Antonella Pansini, Nicola Virtuoso, Armando Pirone, Germano Guerra, Veronica Verri, Gaetano Macina, Alessandro Taurino, Klara Komici, Pasquale Mone
Hypertension and chronic kidney disease (CKD) pose significant public health challenges, sharing intertwined pathophysiological mechanisms. Prediabetes is recognized as a precursor to diabetes and is often accompanied by cardiovascular comorbidities such as hypertension, elevating the risk of pre-frailty and frailty. Albuminuria is a hallmark of organ damage in hypertension amplifying the risk of pre-frailty
-
Factors influencing hospitalization or emergency department visits and mortality in type 2 diabetes following the onset of new cardiovascular diagnoses in a population-based study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-10 Björn Agvall, Junmei Miao Jonasson, Alexander Galozy, Anders Halling
Individuals with type 2 diabetes (T2D) are at increased risk of developing cardiovascular disease (CVD) which necessitates monitoring of risk factors and appropriate pharmacotherapy. This study aimed to identify factors predicting emergency department visits, hospitalizations, and mortality among T2D patients after being newly diagnosed with CVD. In a retrospective observational study conducted in
-
Oral-gut microbial transmission promotes diabetic coronary heart disease Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-05 Yiwen Li, Yanfei Liu, Jing Cui, Mengmeng Zhu, Wenting Wang, Keji Chen, Luqi Huang, Yue Liu
Diabetes is a predominant driver of coronary artery disease worldwide. This study aims to unravel the distinct characteristics of oral and gut microbiota in diabetic coronary heart disease (DCHD). Simultaneously, we aim to establish a causal link between the diabetes-driven oral-gut microbiota axis and increased susceptibility to diabetic myocardial ischemia–reperfusion injury (MIRI). We comprehensively
-
Repressive H3K27me3 drives hyperglycemia-induced oxidative and inflammatory transcriptional programs in human endothelium Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-05 Julia Sánchez-Ceinos, Shafaat Hussain, Abdul Waheed Khan, Liang Zhang, Wael Almahmeed, John Pernow, Francesco Cosentino
Histone modifications play a critical role in chromatin remodelling and regulate gene expression in health and disease. Histone methyltransferases EZH1, EZH2, and demethylases UTX, JMJD3, and UTY catalyse trimethylation of lysine 27 on histone H3 (H3K27me3). This study was designed to investigate whether H3K27me3 triggers hyperglycemia-induced oxidative and inflammatory transcriptional programs in
-
Association between triglyceride–glucose index trajectories and radiofrequency ablation outcomes in patients with stage 3D atrial fibrillation Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-05 Sixiang Jia, Yanping Yin, Xuanting Mou, Jing Zheng, Zhe Li, Tianli Hu, Jianqiang Zhao, Jiangbo Lin, Jiaqi Song, Fanli Cheng, Yiran Wang, Kaini Li, Wenting Lin, Chao Feng, Weili Ge, Shudong Xia
This study investigates the relationship between triglyceride-glucose (TyG) index trajectories and the results of ablation in patients with stage 3D atrial fibrillation (AF). A retrospective cohort study was carried out on patients who underwent AF Radiofrequency Catheter Ablation (RFCA) at the Cardiology Department of the Fourth Affiliated Hospital of Zhejiang University and Taizhou Hospital of Zhejiang
-
The effect of hyperlipidemia and body fat distribution on subclinical left ventricular function in obesity: a cardiovascular magnetic resonance study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-02 Jing Liu, Jing Li, Chunchao Xia, Wenzhang He, Xue Li, Sumin Shen, Xiaoyue Zhou, Nanwei Tong, Liqing Peng
Obesity is often associated with multiple comorbidities. However, whether obese subjects with hyperlipidemia in the absence of other complications have worse cardiac indices than metabolically healthy obese subjects is unclear. Therefore, we aimed to determine the effect of hyperlipidemia on subclinical left ventricular (LV) function in obesity and to evaluate the association of cardiac parameters
-
The association of atherogenic index of plasma with cardiovascular outcomes in patients with coronary artery disease: A systematic review and meta-analysis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-02 Mehrdad Rabiee Rad, Ghazal Ghasempour Dabaghi, Bahar Darouei, Reza Amani-Beni
Atherogenic index of plasma (AIP) represents a novel marker in the current era of cardiovascular diseases. In this meta-analysis, we aimed to evaluate the association of AIP with cardiovascular prognosis in patients with coronary artery disease (CAD). PubMed, Scopus, and Web of Science databases were searched from inception through 2024. The primary outcome was major cardiovascular events (MACE). The
-
Sodium-glucose cotransporter 2 inhibitors, inflammation, and heart failure: a two-sample Mendelian randomization study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-02 Wenqin Guo, Lingyue Zhao, Weichao Huang, Jing Chen, Tingting Zhong, Shaodi Yan, Wei Hu, Fanfang Zeng, Changnong Peng, Hongbing Yan
Sodium-glucose cotransporter 2 (SGLT-2) inhibitors are increasingly recognized for their role in reducing the risk and improving the prognosis of heart failure (HF). However, the precise mechanisms involved remain to be fully delineated. Evidence points to their potential anti-inflammatory pathway in mitigating the risk of HF. A two-sample, two-step Mendelian Randomization (MR) approach was employed
-
The neutrophil-to-lymphocyte ratio is associated with all-cause and cardiovascular mortality among individuals with hypertension Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-02 Xuexue Zhang, Rui Wei, Xujie Wang, Wantong Zhang, Mengxuan Li, Tian Ni, Weiliang Weng, Qiuyan Li
Identifying reliable prognostic markers is crucial for the effective management of hypertension. The neutrophil-to-lymphocyte ratio (NLR) has emerged as a potential inflammatory marker linked to cardiovascular outcomes. This study aims to investigate the association of NLR with all-cause and cardiovascular mortality among patients with hypertension. This study analyzed data from 3067 hypertensive adults
-
Irisin attenuates type 1 diabetic cardiomyopathy by anti-ferroptosis via SIRT1-mediated deacetylation of p53 Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-04-02 Yuan-juan Tang, Zhen Zhang, Tong Yan, Ken Chen, Guo-fan Xu, Shi-qiang Xiong, Dai-qian Wu, Jie Chen, Pedro A. Jose, Chun-yu Zeng, Jin-juan Fu
Diabetic cardiomyopathy (DCM) is a serious complication in patients with type 1 diabetes mellitus (T1DM), which still lacks adequate therapy. Irisin, a cleavage peptide off fibronectin type III domain-containing 5, has been shown to preserve cardiac function in cardiac ischemia–reperfusion injury. Whether or not irisin plays a cardioprotective role in DCM is not known. T1DM was induced by multiple
-
Effect of physical activity on incident atrial fibrillation in individuals with varying duration of diabetes: a nationwide population study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-30 JungMin Choi, So‑Ryoung Lee, Eue-Keun Choi, Kyung-Yeon Lee, Hyo-Jeong Ahn, Soonil Kwon, Kyung‑Do Han, Seil Oh, Gregory Y. H. Lip
Diabetes mellitus (DM) duration affects incident atrial fibrillation (AF) risk; the effect of physical activity on mitigating AF risk related to varying DM duration remains unknown. We assessed the effect of physical activity on incident AF in patients with DM with respect to known DM duration. Patients with type 2 DM who underwent the Korean National Health Insurance Service health examination in
-
Elevated levels of plasma inactive stromal cell derived factor-1α predict poor long-term outcomes in diabetic patients following percutaneous coronary intervention Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-30 Yuichi Chikata, Hiroshi Iwata, Katsutoshi Miyosawa, Ryo Naito, Takuma Koike, Soshi Moriya, Hidetoshi Yasuda, Takehiro Funamizu, Shinichiro Doi, Hirohisa Endo, Hideki Wada, Manabu Ogita, Tomotaka Dohi, Takatoshi Kasai, Kikuo Isoda, Shinya Okazaki, Katsumi Miyauchi, Tohru Minamino
Since the complication of diabetes mellitus (DM) is a risk for adverse cardiovascular outcomes in patients with coronary artery disease (CAD), appropriate risk estimation is needed in diabetic patients following percutaneous coronary intervention (PCI). However, there is no useful biomarker to predict outcomes in this population. Although stromal cell derived factor-1α (SDF-1α), a circulating chemokine
-
Risk analysis of the association between different hemoglobin glycation index and poor prognosis in critical patients with coronary heart disease-A study based on the MIMIC-IV database Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-30 Xing Wei, Xinghua Chen, Zhipeng Zhang, Jing Wei, Ben Hu, Nv Long, Jun Feng, Chunmiao Luo
The hemoglobin glycation index (HGI) is the difference between the observed and predicted values of glycosylated hemoglobin (HbA1c), which is closely associated with a variety of poor prognoses. However, there are still no studies on the correlation between HGI and poor prognosis in patients with critical coronary artery disease. The purpose of this study was to analyze the correlation between HGI
-
Evidence that tirzepatide protects against diabetes-related cardiac damages Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-30 Fatemeh Taktaz, Lucia Scisciola, Rosaria Anna Fontanella, Ada Pesapane, Puja Ghosh, Martina Franzese, Giovanni Tortorella, Armando Puocci, Eduardo Sommella, Giuseppe Signoriello, Fabiola Olivieri, Michelangela Barbieri, Giuseppe Paolisso
Glucagon-like peptide-1 receptor agonists (GLP-1RAs) are effective antidiabetic drugs with potential cardiovascular benefits. Despite their well-established role in reducing the risk of major adverse cardiovascular events (MACE), their impact on heart failure (HF) remains unclear. Therefore, our study examined the cardioprotective effects of tirzepatide (TZT), a novel glucose-dependent insulinotropic
-
Associations of triglyceride-glucose (TyG) index with chest pain incidence and mortality among the U.S. population Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-30 Yao Zhao, Yu Gu, Bili Zhang
The triglyceride and glucose (TyG) index, a simple surrogate marker of insulin resistance, is related to cardiovascular disease. However, there is a lack of evidence for the relationship between the TyG index and chest pain. This study aimed to investigate the association of the TyG index with chest pain and to evaluate the relationship between the TyG index and all-cause mortality in participants
-
Sex-specific trends in incidence of first myocardial infarction among people with and without diabetes between 1985 and 2016 in a German region Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-30 Heiner Claessen, Maria Narres, Margit Heier, Tatjana Kvitkina, Birgit Linkohr, Georg Wolff, Michael Roden, Andrea Icks, Annette Peters
The reduction of myocardial infarction (MI) and narrowing the gap between the populations with and without diabetes are important goals of diabetes care. We analyzed time trends for sex-specific incidence rates (IR) of first MI (both non-fatal MI and fatal MI) as well as separately for first non-fatal MI and fatal MI in the population with and without diabetes. Using data from the KORA myocardial infarction
-
Lipidome characterisation and sex-specific differences in type 1 and type 2 diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-29 Maria Barranco-Altirriba, Núria Alonso, Ralf J. M. Weber, Gavin R. Lloyd, Marta Hernandez, Oscar Yanes, Jordi Capellades, Andris Jankevics, Catherine Winder, Mireia Falguera, Josep Franch-Nadal, Warwick B Dunn, Alexandre Perera-Lluna, Esmeralda Castelblanco, Didac Mauricio
In this study, we evaluated the lipidome alterations caused by type 1 diabetes (T1D) and type 2 diabetes (T2D), by determining lipids significantly associated with diabetes overall and in both sexes, and lipids associated with the glycaemic state. An untargeted lipidomic analysis was performed to measure the lipid profiles of 360 subjects (91 T1D, 91 T2D, 74 with prediabetes and 104 controls (CT))
-
Coronary inflammation based on pericoronary adipose tissue attenuation in type 2 diabetic mellitus: effect of diabetes management Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-29 Yuankang Liu, Lisong Dai, Yue Dong, Cong Ma, Panpan Cheng, Cuiping Jiang, Hongli Liao, Ying Li, Xiang Wang, Xiangyang Xu
Coronary inflammation plays crucial role in type 2 diabetes mellitus (T2DM) induced cardiovascular complications. Both glucose-lowering drug interventions (GLDIS) and glycemic control (GC) status potentially correlate coronary inflammation, as indicated by changes in pericoronary adipose tissue (PCAT) attenuation, and thus influence cardiovascular risk. This study evaluated the impact of GLDIS and
-
Persistent epigenetic signals propel a senescence-associated secretory phenotype and trained innate immunity in CD34+ hematopoietic stem cells from diabetic patients Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-29 Maria Cristina Vinci, Sarah Costantino, Giulia Damiano, Erica Rurali, Raffaella Rinaldi, Vera Vigorelli, Annalisa Sforza, Ermes Carulli, Sergio Pirola, Giorgio Mastroiacovo, Angela Raucci, Assam El-Osta, Francesco Paneni, Giulio Pompilio
Diabetes-induced trained immunity contributes to the development of atherosclerosis and its complications. This study aimed to investigate in humans whether epigenetic signals involved in immune cell activation and inflammation are initiated in hematopoietic stem/progenitor cells (HSPCs) and transferred to differentiated progeny. High glucose (HG)-exposure of cord blood (CB)-derived HSPCs induced a
-
Association of sodium-glucose cotransporter 2 inhibitors with risk of major adverse cardiovascular events in type 2 diabetes patients with acute coronary syndrome: a propensity score‑matched analysis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-25 Tao Liu, Zeyuan Fan, Bing Xiao, Chang He, Shicong Wang
This study aimed to investigate the association of sodium-glucose cotransporter 2 inhibitors (SGLT2i) use with cardiovascular (CV) clinical outcomes in type 2 diabetes (T2D) patients with acute coronary syndrome (ACS). Data of T2D patients hospitalized for ACS at Civil Aviation General Hospital from January 2019 to December 2022 were collected. Based on SGLT2i use or not, patients were stratified as
-
Protective effects of imeglimin on the development of atherosclerosis in ApoE KO mice treated with STZ Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-19 Junpei Sanada, Tomohiko Kimura, Masashi Shimoda, Yuichiro Iwamoto, Hideyuki Iwamoto, Kazunori Dan, Yoshiro Fushimi, Yukino Katakura, Yuka Nogami, Yoshiko Shirakiya, Yuki Yamasaki, Tomoko Ikeda, Shuhei Nakanishi, Tomoatsu Mune, Kohei Kaku, Hideaki Kaneto
Imeglimin is a new anti-diabetic drug which promotes insulin secretion from pancreatic β-cells and reduces insulin resistance in insulin target tissues. However, there have been no reports examining the possible anti-atherosclerotic effects of imeglimin. In this study, we investigated the possible anti-atherosclerotic effects of imeglimin using atherosclerosis model ApoE KO mice treated with streptozotocin
-
CVOT Summit Report 2023: new cardiovascular, kidney, and metabolic outcomes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-19 Oliver Schnell, Katharine Barnard-Kelly, Tadej Battelino, Antonio Ceriello, Helena Elding Larsson, Beatriz Fernández-Fernández, Thomas Forst, Juan-Pablo Frias, James R. Gavin, Francesco Giorgino, Per-Henrik Groop, Hiddo J. L. Heerspink, Stephan Herzig, Michael Hummel, George Huntley, Mahmoud Ibrahim, Baruch Itzhak, Stephan Jacob, Linong Ji, Mikhail Kosiborod, Nebosja Lalic, Sofia Macieira, Rayaz A
The 9th Cardiovascular Outcome Trial (CVOT) Summit: Congress on Cardiovascular, Kidney, and Metabolic Outcomes was held virtually on November 30-December 1, 2023. This reference congress served as a platform for in-depth discussions and exchange on recently completed outcomes trials including dapagliflozin (DAPA-MI), semaglutide (SELECT and STEP-HFpEF) and bempedoic acid (CLEAR Outcomes), and the advances
-
Correction: Cardiorenal effectiveness of empagliflozin vs. glucagon-like peptide-1 receptor agonists: final-year results from the EMPRISE study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-18 Phyo T. Htoo, Helen Tesfaye, Sebastian Schneeweiss, Deborah J. Wexler, Brendan M. Everett, Robert J. Glynn, Niklas Schmedt, Lisette Koeneman, Anouk Déruaz-Luyet, Julie M. Paik, Elisabetta Patorno
Correction: Cardiovascular Diabetology (2024) 23:57 https://doi.org/10.1186/s12933-024-02150-0 Following publication of the original article [1], the authors noticed an error in the hazard ratio (HR) for the hospitalization for heart failure (HHF) outcome in the abstract. The numbers in the other parts of the manuscript and the tables were correct. In abstract section, the correct sentence should read
-
Prevalence and prognostic significance of cardiac autonomic neuropathy in community-based people with type 2 diabetes: the Fremantle Diabetes Study Phase II Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-18 Timothy M. E. Davis, Eva Tan, Wendy A. Davis
There is a paucity of contemporary data on the prevalence and prognostic significance of cardiac autonomic neuropathy (CAN) from community-based cohorts with type 2 diabetes assessed using gold standard methods. The aim of this study was to assess these aspects of CAN in the longitudinal observational Fremantle Diabetes Study Phase II (FDS2). FDS2 participants were screened at baseline using standardised
-
Postpartum weight retention and the early evolution of cardiovascular risk over the first 5 years after pregnancy Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-18 Caroline K. Kramer, Chang Ye, Anthony J Hanley, Philip W Connelly, Mathew Sermer, Bernard Zinman, Ravi Retnakaran
The cumulative effect of postpartum weight retention from each pregnancy in a woman’s life may contribute to her risk of ultimately developing type 2 diabetes and cardiovascular disease. However, there is limited direct evidence supporting this hypothesis. Thus, we sought to characterize the impact of postpartum weight retention on the trajectories of cardiovascular risk factors over the first 5-years
-
Triglyceride-glucose index: a novel evaluation tool for all-cause mortality in critically ill hemorrhagic stroke patients-a retrospective analysis of the MIMIC-IV database Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-18 Yongwei Huang, Zongping Li, Xiaoshuang Yin
Hemorrhagic stroke (HS), including non-traumatic intracerebral hemorrhage (ICH) and subarachnoid hemorrhage (SAH), constitutes a substantial proportion of cerebrovascular incidents, accounting for around 30% of stroke cases. The triglyceride-glucose index (TyG-i) represents a precise insulin resistance (IR) indicator, a crucial metabolic disturbance. Existing literature has demonstrated an association
-
Effectiveness and safety of the combination of sodium–glucose transport protein 2 inhibitors and glucagon-like peptide-1 receptor agonists in patients with type 2 diabetes mellitus: a systematic review and meta-analysis of observational studies Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-18 Aftab Ahmad, Hani Sabbour
Randomized controlled trials and real-world studies suggest that combination therapy with sodium–glucose transport protein 2 inhibitors (SGLT2is) and glucagon-like peptide-1 receptor agonists (GLP-1RAs) is associated with improvement in fasting plasma glucose (FPG), glycated hemoglobin (HbA1c), systolic blood pressure (SBP), body mass index (BMI), and total cholesterol levels. However, a systematic
-
Telomere length as biomarker of nutritional therapy for prevention of type 2 diabetes mellitus development in patients with coronary heart disease: CORDIOPREV randomised controlled trial Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-16 Ana Ojeda-Rodriguez, Oriol A. Rangel-Zuñiga, Antonio P. Arenas-de Larriva, Francisco M. Gutierrez-Mariscal, Jose D. Torres-Peña, Juan L. Romero-Cabrera, Alicia Podadera-Herreros, Helena García-Fernandez, Esther Porras-Pérez, Raul M. Luque, Stefanos N. Kales, Pablo Perez-Martinez, Javier Delgado-Lista, Elena M. Yubero-Serrano, Jose Lopez-Miranda
Telomere Length (TL), a marker of cellular aging, holds promise as a biomarker to elucidate the molecular mechanism of diabetes. This study aimed to investigate whether shorter telomeres are associated with a higher risk of type 2 diabetes mellitus (T2DM) incidence in patients with coronary heart disease; and to determine whether the most suitable dietary patterns, particularly a Mediterranean diet
-
Hepatic insulin resistance and muscle insulin resistance are characterized by distinct postprandial plasma metabolite profiles: a cross-sectional study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-16 Anouk Gijbels, Balázs Erdős, Inez Trouwborst, Kelly M. Jardon, Michiel E. Adriaens, Gijs H. Goossens, Ellen E. Blaak, Edith J. M. Feskens, Lydia A. Afman
Tissue-specific insulin resistance (IR) predominantly in muscle (muscle IR) or liver (liver IR) has previously been linked to distinct fasting metabolite profiles, but postprandial metabolite profiles have not been investigated in tissue-specific IR yet. Given the importance of postprandial metabolic impairments in the pathophysiology of cardiometabolic diseases, we compared postprandial plasma metabolite
-
MCT4-dependent lactate transport: a novel mechanism for cardiac energy metabolism injury and inflammation in type 2 diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-14 Xiu Mei Ma, Kang Geng, Peng Wang, Zongzhe Jiang, Betty Yuen-Kwan Law, Yong Xu
Diabetic cardiomyopathy (DCM) is a major contributor to mortality in diabetic patients, characterized by a multifaceted pathogenesis and limited therapeutic options. While lactate, a byproduct of glycolysis, is known to be significantly elevated in type 2 diabetes, its specific role in DCM remains uncertain. This study reveals an abnormal upregulation of monocarboxylate transporter 4 (MCT4) on the
-
Association between triglyceride-glucose index and intracranial/extracranial atherosclerotic stenosis: findings from a retrospective study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-14 Yu Xie, Kuan Cen, Bitang Dan, Li Zou, Lei Zhang, Renwei Zhang, Huagang Li, Qi Cai, Nadire Aiziretiaili, Zhenxing Liu, Yumin Liu
The association of the triglyceride-glucose (TyG) index with intracranial atherosclerotic stenosis (ICAS) and extracranial atherosclerotic stenosis (ECAS) is unclear. This study aimed to investigate the relationship of TyG index with the distribution and severity of ICAS and ECAS. Patients who underwent digital subtraction angiography (DSA) for evaluating ICAS/ECAS in Zhongnan Hospital of Wuhan University
-
Underlying mechanisms and cardioprotective effects of SGLT2i and GLP-1Ra: insights from cardiovascular magnetic resonance Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-11 Angelica Cersosimo, Nadia Salerno, Jolanda Sabatino, Alessandra Scatteia, Giandomenico Bisaccia, Salvatore De Rosa, Santo Dellegrottaglie, Chiara Bucciarelli-Ducci, Daniele Torella, Isabella Leo
Originally designed as anti-hyperglycemic drugs, Glucagon-Like Peptide-1 receptor agonists (GLP-1Ra) and Sodium-glucose cotransporter-2 inhibitors (SGLT2i) have demonstrated protective cardiovascular effects, with significant impact on cardiovascular morbidity and mortality. Despite several mechanisms have been proposed, the exact pathophysiology behind these effects is not yet fully understood. Cardiovascular
-
The relative and combined ability of stress hyperglycemia ratio and N-terminal pro-B-type natriuretic peptide to predict all-cause mortality in diabetic patients with multivessel coronary artery disease Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-11 Le Wang, Chen Wang, Jia-chun Lang, Rong-di Xu, Hong‑liang Cong, Jing‑xia Zhang, Yue‑cheng Hu, Ting-ting Li, Chun-wei Liu, Hua Yang, Wen‑yu Li
Stress hyperglycemia ratio (SHR) and N-terminal pro-B-type natriuretic peptide (NT-proBNP) are independently associated with increased mortality risk in diabetic patients with coronary artery disease (CAD). However, the role of these biomarkers in patients with diabetes and multivessel disease (MVD) remains unknown. The present study aimed to assess the relative and combined abilities of these biomarkers
-
Sex differences in the relationship between serum total bilirubin and risk of incident metabolic syndrome in community-dwelling adults: Propensity score analysis using longitudinal cohort data over 16 years Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-11 Ae Hee Kim, Da-Hye Son, Mid-Eum Moon, Soyoung Jeon, Hye Sun Lee, Yong-Jae Lee
Research on identifiable risks for metabolic syndrome (MetS) is ongoing, and growing evidence suggests that bilirubin is a potent antioxidant and cytoprotective agent against MetS. However, there have been conflicting results on the association between bilirubin and MetS. Our study aimed to validate the association by separately stratifying data for men and women in a longitudinal prospective study
-
Use of the energy waveform electrocardiogram to detect subclinical left ventricular dysfunction in patients with type 2 diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-06 Cheng Hwee Soh, Alex G. C. de Sá, Elizabeth Potter, Amera Halabi, David B. Ascher, Thomas H. Marwick
Recent guidelines propose N-terminal pro-B-type natriuretic peptide (NT-proBNP) for recognition of asymptomatic left ventricular (LV) dysfunction (Stage B Heart Failure, SBHF) in type 2 diabetes mellitus (T2DM). Wavelet Transform based signal-processing transforms electrocardiogram (ECG) waveforms into an energy distribution waveform (ew)ECG, providing frequency and energy features that machine learning
-
The worsening effect of paroxysmal atrial fibrillation on left ventricular function and deformation in type 2 diabetes mellitus patients: a 3.0 T cardiovascular magnetic resonance feature tracking study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-06 Xue-Ming Li, Wei-Feng Yan, Ke Shi, Rui Shi, Li Jiang, Yue Gao, Chen-Yan Min, Xiao-Jing Liu, Ying-Kun Guo, Zhi-Gang Yang
Atrial fibrillation (AF) has been linked to an increased risk of cardiovascular death, overall mortality and heart failure in patients with type 2 diabetes mellitus (T2DM). The present study investigated the additive effects of paroxysmal AF on left ventricular (LV) function and deformation in T2DM patients with or without AF using the cardiovascular magnetic resonance feature tracking (CMR-FT) technique
-
Mean platelet volume (MPV) as new marker of diabetic macrovascular complications in patients with different glucose homeostasis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-03-02 Velia Cassano, Giuseppe Armentaro, Domenico Iembo, Sofia Miceli, Teresa V. Fiorentino, Elena Succurro, Maria Perticone, Franco Arturi, Marta L. Hribal, Tiziana Montalcini, Francesco Andreozzi, Giorgio Sesti, Arturo Pujia, Angela Sciacqua
Platelets play an important role in the development of cardiovascular disease (CVD). Mean platelet volume (MPV) is considered as biological marker of platelets activity and function. The aim of the present study was to evaluate MPV values and its possible correlation with arterial stiffness and subclinical myocardial damage, in normal glucose tolerance patients (NGT), in newly diagnosed type 2 diabetic
-
The SGLT2 inhibitor Empagliflozin promotes post-stroke functional recovery in diabetic mice Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-29 Ellen Vercalsteren, Dimitra Karampatsi, Carolina Buizza, Thomas Nyström, Thomas Klein, Gesine Paul, Cesare Patrone, Vladimer Darsalia
Type-2 diabetes (T2D) worsens stroke recovery, amplifying post-stroke disabilities. Currently, there are no therapies targeting this important clinical problem. Sodium-glucose cotransporter 2 inhibitors (SGLT2i) are potent anti-diabetic drugs that also efficiently reduce cardiovascular death and heart failure. In addition, SGLT2i facilitate several processes implicated in stroke recovery. However,
-
Non-insulin-based insulin resistance indexes in predicting atrial fibrillation recurrence following ablation: a retrospective study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Zhe Wang, Haoming He, Yingying Xie, Jiaju Li, Fangyuan Luo, Zhaowei Sun, Shuwen Zheng, Furong Yang, Xuexi Li, Xiaojie Chen, Yingwei Chen, Yihong Sun
Insulin resistance (IR) is involved in the pathophysiological processes of arrhythmias. Increasing evidence suggests triglyceride and glucose (TyG) index, metabolic score for insulin resistance (METS-IR), triglyceride glucose-body mass index (TyG-BMI), and triglyceride to high-density lipoprotein cholesterol (TG/HDL-C) ratio are simple and reliable surrogates for IR. Although they have been associated
-
Association between different insulin resistance surrogates and all-cause mortality in patients with coronary heart disease and hypertension: NHANES longitudinal cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Xin-Zheng Hou, Yan-Fei Lv, Yu-Shan Li, Qian Wu, Qian-Yu Lv, Ying-Tian Yang, Lan-Lan Li, Xue-Jiao Ye, Chen-Yan Yang, Man-Shi Wang, Lin-Lin Cao, Shi-Han Wang
Studies on the relationship between insulin resistance (IR) surrogates and long-term all-cause mortality in patients with coronary heart disease (CHD) and hypertension are lacking. This study aimed to explore the relationship between different IR surrogates and all-cause mortality and identify valuable predictors of survival status in this population. The data came from the National Health and Nutrition
-
Fatty liver index is an independent risk factor for all-cause mortality and major cardiovascular events in type 1 diabetes: an 11-year observational study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Monia Garofolo, Daniela Lucchesi, Massimo Giambalvo, Michele Aragona, Alessandra Bertolotto, Fabrizio Campi, Cristina Bianchi, Paolo Francesconi, Piero Marchetti, Stefano Del Prato, Giuseppe Penno
Non-alcoholic fatty liver disease (NAFLD), identified by the Fatty Liver Index (FLI), is associated with increased mortality and cardiovascular (CV) outcomes. Whether this also applies to type 1 diabetes (T1D) has not been yet reported. We prospectively observed 774 subjects with type 1 diabetes (males 52%, 30.3 ± 11.1 years old, diabetes duration (DD) 18.5 ± 11.6 years, HbA1c 7.8 ± 1.2%) to assess
-
The prognostic value of the stress hyperglycemia ratio for all-cause and cardiovascular mortality in patients with diabetes or prediabetes: insights from NHANES 2005–2018 Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-28 Lei Ding, Hongda Zhang, Cong Dai, Aikai Zhang, Fengyuan Yu, Lijie Mi, Yingjie Qi, Min Tang
The Stress hyperglycemia ratio (SHR) is a novel marker reflecting the true acute hyperglycemia status and is associated with clinical adverse events. The relationship between SHR and mortality in patients with diabetes or prediabetes is still unclear. This study aimed to investigate the predictive value of the SHR for all-cause and cardiovascular mortality in patients with diabetes or prediabetes.
-
Distribution and prognostic value of high-sensitivity cardiac troponin T and I across glycemic status: a population-based study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Jiajun Zhang, Xiaoxing Li, Shenglin Zhang, Zhen Wang, Rui Tian, Feng Xu, Yuguo Chen, Chuanbao Li
Whether distributions and prognostic values of high-sensitivity cardiac troponin (hs-cTn) T and I are different across normoglycemic, prediabetic, and diabetic populations is unknown. 10127 adult participants from the National Health and Nutrition Examination Survey 1999–2004 with determined glycemic status and measurement of at least one of hs-cTn assays were included, from whom healthy participants
-
Intensive lifestyle intervention in type 2 diabetes and risk of incident coronary artery disease for the common haptoglobin phenotypes: the Look AHEAD study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Rachel A. Warren, Michael P. Bancks, Allie S. Carew, Andrew P. Levy, John Sapp, Judy Bahnson, Cora E. Lewis, Eric B. Rimm, Mark A. Espeland, Leah E. Cahill
Intensive glycemic control reduced coronary artery disease (CAD) events among the Action to Control Cardiovascular Disease Risk in Diabetes (ACCORD) participants with the haptoglobin (Hp) 2-2 phenotype only. It remains unknown whether Hp phenotype modifies the effect of an intensive lifestyle intervention (ILI) on CAD in type 2 diabetes. Haptoglobin phenotype was measured in 4542 samples from the Action
-
Link between triglyceride-glucose-body mass index and future stroke risk in middle-aged and elderly chinese: a nationwide prospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Yuankai Shao, Haofei Hu, Qiming Li, Changchun Cao, Dehong Liu, Yong Han
Current literature is deficient in robust evidence delineating the correlation between the triglyceride glucose-body mass index (TyG-BMI) and the incidence of stroke. Consequently, this investigation seeks to elucidate the potential link between TyG-BMI and stroke risk in a cohort of middle-aged and senior Chinese individuals. This study employs longitudinal data from four waves of the China Health
-
Association of the triglyceride-glucose index with all-cause and cardiovascular mortality in patients with cardiometabolic syndrome: a national cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Quanjun Liu, Yeshen Zhang, Shuhua Chen, Hong Xiang, Jie Ouyang, Huiqin Liu, Jing Zhang, Yanfei Chai, Zishun Zhan, Peng Gao, Xiao Zhang, Jianing Fan, Xinru Zheng, Zhihui Zhang, Hongwei Lu
This study aimed to evaluate the association of triglyceride-glucose (TyG) index with all-cause and cardiovascular mortality risk among patients with cardiometabolic syndrome (CMS). We performed a cohort study of 5754 individuals with CMS from the 2001–2018 National Health and Nutrition Examination Survey. The TyG index was calculated as Ln [fasting triglycerides (mg/dL) × fasting glucose (mg/dL)/2]
-
Insulin resistance and coronary inflammation in patients with coronary artery disease: a cross-sectional study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Tingjie Yang, Guoyong Li, Che Wang, Guian Xu, Qingman Li, Yapan Yang, Lijie Zhu, Lulin Chen, Xueqing Li, Honghui Yang
Insulin resistance (IR) is associated with coronary artery disease (CAD) severity. However, its underlying mechanisms are not fully understood. Therefore, our study aimed to explore the relationship between IR and coronary inflammation and investigate the synergistic and mediating effects of coronary inflammation on the association between IR and CAD severity. Consecutive patients with CAD who underwent
-
Effect of SGLT-2 inhibitors on arrhythmia events: insight from an updated secondary analysis of > 80,000 patients (the SGLT2i—Arrhythmias and Sudden Cardiac Death) Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-24 Jia Liao, Ramin Ebrahimi, Zhiyu Ling, Christian Meyer, Martin Martinek, Philipp Sommer, Piotr Futyma, Davide Di Vece, Alexandra Schratter, Willem-Jan Acou, Lin Zhu, Márcio G. Kiuchi, Shaowen Liu, Yuehui Yin, Helmut Pürerfellner, Christian Templin, Shaojie Chen
We aimed to assess the effect of SGLT2i on arrhythmias by conducting a meta-analysis using data from randomized controlled trials(RCTs). Sodium-glucose co-transporter 2 inhibitors (SGLT2i) have shown cardioprotective effects via multiple mechanisms that may also contribute to decrease arrhythmias risk. We searched in databases (PubMed, Embase, Cochrane Library, and clinicaltrials.gov) up to April 2023
-
The association between the AIP and undiagnosed diabetes in ACS patients with different body mass indexes and LDL-C levels: findings from the CCC-ACS project Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Shuwan Xu, Jun Liu, Dong Zhao, Na Yang, Yongchen Hao, Yan Zhou, Dan Zhu, Ming Cui
The atherogenic index of plasma (AIP) has been demonstrated to be significantly associated with the incidence of prediabetes and diabetes. This study aimed to investigate the association between the AIP and undiagnosed diabetes in acute coronary syndrome (ACS) patients. Among 113,650 ACS patients treated with coronary angiography at 240 hospitals in the Improving Care for Cardiovascular Disease in
-
Associations of the triglyceride-glucose index and atherogenic index of plasma with the severity of new-onset coronary artery disease in different glucose metabolic states Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Xiaosheng Wu, Weiping Qiu, Huancheng Yang, Yan-Jun Chen, Jianling Liu, Guojun Zhao
The triglyceride-glucose (TyG) index is considered a dependable biomarker for gauging insulin resistance. The atherogenic index of plasma (AIP) represents a marker reflecting atherosclerosis. However, there is currently no study specifically exploring the associations of these two biomarkers with the severity of new-onset coronary artery disease (CAD) under different glucose metabolic states. Therefore
-
Mechanisms of endothelial activation, hypercoagulation and thrombosis in COVID-19: a link with diabetes mellitus Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Inés Valencia, Jairo Lumpuy-Castillo, Giselle Magalhaes, Carlos F. Sánchez-Ferrer, Óscar Lorenzo, Concepción Peiró
Early since the onset of the COVID-19 pandemic, the medical and scientific community were aware of extra respiratory actions of SARS-CoV-2 infection. Endothelitis, hypercoagulation, and hypofibrinolysis were identified in COVID-19 patients as subsequent responses of endothelial dysfunction. Activation of the endothelial barrier may increase the severity of the disease and contribute to long-COVID syndrome
-
Correction: Heparanase inhibition as a systemic approach to protect the endothelial glycocalyx and prevent microvascular complications in diabetes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-20 Monica Gamez, Hesham E. Elhegni, Sarah Fawaz, Kwan Ho Ho, Neill W. Campbell, David A. Copland, Karen L. Onions, Matthew J. Butler, Elizabeth J. Wasson, Michael Crompton, Raina D. Ramnath, Yan Qiu, Yu Yamaguchi, Kenton P. Arkill, David O. Bates, Jeremy E. Turnbull, Olga V. Zubkova, Gavin I. Welsh, Denize Atan, Simon C. Satchell, Rebecca R. Foster
Following publication of the original article [1], the author noticed the error in Discussion section. In the last paragraph under Discussion section, the sentence “The heterogenous nature of oligo-/polysaccharide derivatives such as PG545 also results in batch variations, further complicating FDA approval” is incorrect. In this text, PG545 should be replaced with SST0001 and should read “The heterogenous
-
Prognostic effect of stress hyperglycemia ratio on patients with severe aortic stenosis receiving transcatheter aortic valve replacement: a prospective cohort study Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-16 Xiangming Hu, Dejing Feng, Yuxuan Zhang, Can Wang, Yang Chen, Guannan Niu, Zheng Zhou, Zhenyan Zhao, Hongliang Zhang, Moyang Wang, Yongjian Wu
Stress hyperglycemia ratio (SHR) has recently been recognized as a novel biomarker that accurately reflects acute hyperglycemia status and is associated with poor prognosis of heart failure. We evaluated the relationship between SHR and clinical outcomes in patients with severe aortic stenosis receiving transcatheter aortic valve replacement (TAVR). There were 582 patients with severe native aortic
-
The effectiveness of sodium-glucose co-transporter 2 inhibitors on cardiorenal outcomes: an updated systematic review and meta-analysis Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-15 Muhammad Usman Ali, G. B. John Mancini, Donna Fitzpatrick-Lewis, Kim A. Connelly, Eileen O’Meara, Shelley Zieroth, Diana Sherifali
The 2022 Canadian Cardiovascular Society (CCS) cardiorenal guideline provided clinical recommendations on sodium-glucose co-transport 2 inhibitors (SGLT2i) and glucagon-like peptide-1 receptor agonists (GLP-1RA) use. Since then, additional trials of relevance for SGLT2i have been published. This update re-evaluates the clinical recommendations for using SGLTi and their indirect comparison with existing
-
Efficacy and safety of enavogliflozin vs. dapagliflozin as add-on therapy in patients with type 2 diabetes mellitus based on renal function: a pooled analysis of two randomized controlled trials Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-15 Young Sang Lyu, Sangmo Hong, Si Eun Lee, Bo Young Cho, Cheol-Young Park
We assessed the efficacy and safety of enavogliflozin (0.3 mg), a newly developed SGLT-2 inhibitor, in patients with type 2 diabetes mellitus based on kidney function via pooled analysis of two 24-week, randomized, double-blind phase III trials. Data from 470 patients were included (enavogliflozin: 0.3 mg/day, n = 235; dapagliflozin: 10 mg/day, n = 235). The subjects were classified by mildly reduced
-
Association of plasma angiogenin with risk of major cardiovascular events in type 2 diabetes Cardiovasc. Diabetol. (IF 9.3) Pub Date : 2024-02-15 Resham L. Gurung, Sylvia Liu, Jian-Jun Liu, Yiamunaa M., Huili Zheng, Clara Chan, Keven Ang, Tavintharan Subramaniam, Chee Fang Sum, Su Chi Lim
Angiogenin, an enzyme belonging to the ribonucleases A superfamily, plays an important role in vascular biology. Here, we sought to study the association of plasma angiogenin and major adverse cardiovascular events (MACEs) in patients with type 2 diabetes (T2D). This prospective study included 1083 T2D individuals recruited from a secondary hospital and a primary care facility. The primary outcome